Silexion Therapeutics Corp (SLXN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.29M
Last updated: Nov 17, 2026 at 11:02 AM ET
Silexion Therapeutics Corp (SLXN) Stock Forecast
Analysts expect Silexion Therapeutics (SLXN) to earn -$112.80 per share in the fiscal year ending Dec 31, 2026. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$44.16.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$112.80
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$44.16
- EPS consensus
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$112.80 | -$112.80 to -$112.80 | 1 |
| Dec 31, 2027 | -$44.16 | -$44.16 to -$44.16 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.72 | N/A | 3 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$127.44.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$112.80 | -$116.28 | -$116.28 | -$119.76 | -$127.44 | N/A |
| Fiscal year ending Dec 31, 2027 | -$44.16 | -$48.60 | -$48.60 | -$446.52 | -$444.36 | N/A |
Frequently Asked Questions About SLXN
What is the SLXN stock forecast?
Consensus analyst estimates put Silexion Therapeutics's EPS at -$112.80 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from SLXN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$112.80, with estimates from -$112.80 to -$112.80 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$44.16, with estimates from -$44.16 to -$44.16 from 1 analyst.
How many analysts cover SLXN?
1 analyst estimates EPS for Silexion Therapeutics for the fiscal year ending Dec 31, 2026.
SLXN pages: Overview, Forecast, Financials, Competitors